Platelet aggregation under high shear conditions during and after a 28-day administration of 100 mg acetylsalicylic acid in healthy volunteers

Clinical Hemorheology and Microcirculation

Volumn 38, Issue 1, 2008, Pages 45-50

  Tschopp, Marcel ^a   Reinhart, Walter H ^a  

^a KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

Author keywords

Aspirin; Platelet aggregation; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; COLLAGEN;

ARTICLE; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MEMBRANE; NORMAL HUMAN; SHEAR RATE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT RESPONSE;

ADULT; ASPIRIN; DRUG MONITORING; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PERFUSION; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; REPRODUCIBILITY OF RESULTS; STRESS, MECHANICAL; TREATMENT OUTCOME;

EID: 37149009188     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. P.A.M.M. Aarts, R.M. Heethaar and J.J. Sixma, Blood platelets are concentrated near the wall and red blood cells in the center in flowing blood, Arteriosclerosis 8 (1988), 819-823.
2. A. Abaci, Y. Yilmaz, M. Caliskan et al., Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes, Thromb. Res. 116 (2005), 465-470.
3. A. Abaci, M. Caliskan, F. Bayram et al., A new definition of aspirin non-responsiveness by platelet function analyzer-100 and its predictors, Platelets 17 (2006), 7-13.
4. M.J. Alberts, D.L. Bergman, E. Molner et al., Antiplatelet effect of aspirin in patients with cerebrovascular disease, Stroke 35 (2004), 175-178.
5. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo et al., Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention, Am. J. Cardiol. 97 (2006), 38-43.
6. Antithrombotic Trialists' Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ 324 (2002), 71-86.
7. J.S. Berger, M.C. Roncaglioni, F. Avanzini et al., Aspirin for the primary prevention of cardiovascular events in women and men. A sex-specific meta-analysis of randomized controlled trials, JAMA 295 (2006), 306-313.
8. R.A. Cahill, G.T. McGreal, B.H. Crowe et al., Duration of increased bleeding tendency after cessation of aspirin therapy, J. Am. Coll. Surg. 200 (2005), 564-573.
9. F. Catella-Lawson, M.P. Reilly, S.C. Kapoor et al., Cyclooxygenase inhibitors and the antiplatelet effects of aspirin, N. Engl. J. Med. 345 (2001), 1809-1817.
10. T. Chakroun, G. Gerotziafas, F. Robert et al., In vitro aspirin resistance detected by PFA-100 closure time: Pivotal role of plasma von Willebrand factor, Br. J. Haematol. 124 (2004), 80-85.
11. I. Coma-Canella, A. Velasco and S. Castano, Prevalence of aspirin resistance measured by PFA-100, Int. J. Cardiol. 101 (2005), 71-76.
12. B. Crowe, S. Abbas, B. Meany et al., Detection of aspirin resistance by PFA-100: Prevalence and aspirin compliance in patients with chronic stable angina, Semin. Thromb. Haemost. 31, (2005), 420-425.
13. J.E. Dalen, Aspirin resistance: Is it real? Is it clinically significant, Am. J. Med. 120 (2007), 1-4.
14. S. Fateh-Moghadam, U. Plockinger, N. Cabeza et al., Prevalence of aspirin resistance in patients with type 2 diabetes, Acta. Diabetol. 42 (2005), 99-103.
15. E. Fressinaud, A. Veyradier, F. Truchaud et al., Screening for von Willebrand disease with a new analyzer using high shear stress, Blood 981 (1998), 1325-1331.
16. J. Gianetti, M.S. Parri, S. Sbrana et al., Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: A 6 months prospective study, Thromb. Res. (2005), Epub ahead of print.
17. N.A. Goldenberg, L. Jacobson and M.J. Manco-Johnson, Brief communication: Duration of platelet dysfunction after a 7-day course of Ibuprofen, Ann. Intern. Med. 142 (2005), 505-509.
18. K.H. Grotemeyer, H.W. Scharafinski and I.W. Husstedt, Two-year follow-up of aspirin responder and aspirin non responder, A pilot-study including 180 post-stroke patients, Thromb. Res. 71 (1993), 397-403.
19. K. Grundmann, K. Jaschonek, B. Kleine et al., Aspirin non-responder status in patients with recurrent cerebral ischemic attacks, J. Neurol. 250 (2003), 63-66.
20. P.A. Gum, K. Kottke-Marchant, E.D. Poggio et al., Profile and prevalence of aspirin resistance in patients with cardiovascular disease, Am. J. Cardiol. 88 (2001), 230-235.
21. P.A. Gum, K. Kottke-Marchant, P.A. Welsh et al., A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease, J. Am. Coll. Cardiol. 41 (2003), 961-965.
22. M.K. Halushka, L.P. Walker and P.V. Halushka, Genetic variation in cyclooxygenase 1: Effects on response to aspirin, Clin. Pharmacol. Ther. 73 (2003), 122-130.
23. G.J. Hankey and J.W. Eikelboom, Aspirin resistance, Lancet 367 (2006), 606-617.
24. P. Harrison, H. Segal, K. Blasbery et al., Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry, Stroke 36 (2005), 1001-1005.
25. A. Jordan, T. David, S. Homer-Vanniasinkam, A. Graham and P. Walker, The effects ofmargination and red cell augmented platelet diffusivity on platelet adhesion in complex flow, Biorheology 41 (2004), 641-653.
26. T. Kawasaki, Y. Ozeki, T. Igawa et al., Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin, Stroke 31 (2000), 591-595.
27. G. Kesmarky , G. Feher, K. Koltai et al., Viscosity, hemostasis and inflammation in atherosclerotic heart diseases, Clin. Hemorheol. Microcirc. 35 (2006), 67-73.
28. J. Koscielny, T. Aslan, O. Meyer et al., Use of the platelet reactivity index by Grotemeyer, platelet function analyzer, and retention test Homburg to monitor therapy with antiplatelet drugs, Semin. Thromb. Hemost. 31 (2005), 464-469.
29. L. Macchi, L. Christiaens, S. Brabant et al., Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate, Thromb. Res. 107 (2002), 45-49.
30. L. Mannini, R. Marcucci, R. Paniccia et al., Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients, Clin. Hemorheol. Microcirc. 35 (2006), 175-181.
31. M.R. Mueller, A. Salat, P. Stangl et al., Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty, Thromb. Haemost. 78 (1997), 1003-1007.
32. C. Patrono, L.A. Garcia Rodriguez, R. Landolfi et al., Low-dose aspirin for the prevention of atherothrombosis, N. Engl. J. Med. 353 (2005), 2373-2383.
33. D.A. Payne, C.I. Jones, P.D. Hayes et al., Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance?, Thromb. Haemost. 92 (2004), 89-96.
34. P. Peterson, T.E. Hayes, C.F. Arkin et al., The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article, Arch. Surg. 133 (1998), 134-139.
35. A. Sambola, M. Heras, G. Escolar et al., The PFA-100 detects sub-optimal antiplatelet responses in patients on aspirin, Platelets 15 (2004), 439-446.
36. S. Sanderson, J. Emery, T. Baglin et al., Narrative review: Aspirin resistance and its clinical implications, Ann. Intern. Med. 142 (2005), 370-380.
37. W.A. Wuillemin, K.M. Gasser, S.S. Zeerleder et al., Evaluation of a platelet function analyser (PFA-100® ) in patients with a bleeding tendency, Swiss. Med. Wkly 132 (2002), 443-448.
38. N. Zimmermann, A. Wenk, U. Kim et al., Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery, Circulation 108 (2003), 542-547.